Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.62 (
caspase-9
)
7,507
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BMP-9
is a potent osteogenic factor; however, its effects on osteoclasts, the bone-resorbing cells, remain unknown. To determine the effects of
BMP-9
on osteoclast formation, activity and survival, we used human cord blood monocytes as osteoclast precursors that form multinucleated osteoclasts in the presence of RANKL and M-CSF in long-term cultures.
BMP-9
did not affect osteoclast formation, but adding
BMP-9
at the end of the culture period significantly increased bone resorption compared to untreated cultures, and reduced both the rate of apoptosis and
caspase-9
activity.
BMP-9
also significantly downregulated the expression of pro-apoptotic Bid, but only after RANKL and M-CSF, which are both osteoclast survival factors, had been eliminated from the culture medium. To investigate the mechanisms involved in the effects of
BMP-9
, we first showed that osteoclasts expressed some BMP receptors, including BMPR-IA, BMPR-IB, ALK1, and BMPR-II. We also found that
BMP-9
was able to induce the phosphorylation of Smad-1/5/8 and ERK 1/2 proteins, but did not induce p38 phosphorylation. Finally, knocking down the BMPR-II receptor abrogated the
BMP-9
-induced ERK-signaling, as well as the increase in bone resorption. In conclusion, these results show for the first time that
BMP-9
directly affects human osteoclasts, enhancing bone resorption and protecting osteoclasts against apoptosis.
BMP-9
signaling in human osteoclasts involves the canonical Smad-1/5/8 pathway, and the ERK pathway.
...
PMID:Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro. 2331 28